Search people, articles, bills, and more
Sickle cell disease is a serious, lifelong genetic blood disorder that affects millions globally, predominantly people of African, Mediterranean, and South Asian descent. It can lead to severe pain, organ damage, stroke, and early death. This bill matters because it continues and significantly boosts federal efforts to combat this disease, ensuring that programs focused on prevention, treatment, and especially the management of its many painful complications can keep running and expand.
If this bill becomes law, it will mean more funding and a broader focus on helping those with sickle cell disease manage their condition and its associated health problems. If it doesn't pass, the existing program's authorization for funding would expire, potentially cutting off vital resources for patients, healthcare providers, and researchers, leaving many vulnerable individuals with less access to the specialized care they need.
No reactions yet. Be the first to weigh in.
Sickle cell disease is a serious, lifelong genetic blood disorder that affects millions globally, predominantly people of African, Mediterranean, and South Asian descent. It can lead to severe pain, organ damage, stroke, and early death. This bill matters because it continues and significantly boosts federal efforts to combat this disease, ensuring that programs focused on prevention, treatment, and especially the management of its many painful complications can keep running and expand.
If this bill becomes law, it will mean more funding and a broader focus on helping those with sickle cell disease manage their condition and its associated health problems. If it doesn't pass, the existing program's authorization for funding would expire, potentially cutting off vital resources for patients, healthcare providers, and researchers, leaving many vulnerable individuals with less access to the specialized care they need.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
| AMOUNT | PROGRAM | TYPE | YEARS |
|---|---|---|---|
| $8,205,000 | Sickle Cell Disease Prevention and Treatment Demonstration Program | discretionary | 2025-2029 |
Lower Costs for Everyday Americans Act
Consolidated Appropriations Act, 2026
Bipartisan Health Care Act
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025